Transgene and NEC Bio Advance TG4050 Development
On April 2, 2026, Transgene, a biotech company focused on virus-based immunotherapies for cancer, and NEC Bio, a subsidiary of NEC Corporation specializing in IT, network, and AI technologies, announced a license agreement to further the clinical development of TG4050 for the adjuvant treatment of resected HPV-negative head and neck cancer, according to GlobeNewswire PE. Under the agreement, Transgene gains access to NEC’s AI-based neoantigen prediction platform, which selects immunogenic mutations for TG4050, an individualized immunotherapy based on an MVA viral vector aimed at preventing relapse and extending disease-free survival in patients after surgery and adjuvant therapy.
Details of the License Agreement
The license allows Transgene to use NEC’s platform for TG4050’s development while NEC maintains full ownership and operational control of the AI technology and provides support for further clinical activities, as outlined in the announcement. NEC will receive a technology access fee of €2.5 million in Transgene shares upon signing and an additional €2.5 million in cash paid in tranches through early 2028. Further payments include milestone-based amounts, with part paid in Transgene shares, plus additional development milestone payments and a double-digit share of any profits or licensing revenues from the program.
TG4050’s Role in Cancer Treatment
TG4050 stimulates the immune system using tumor-specific neoantigens identified by NEC’s machine learning platform to target each patient’s unique tumor in head and neck cancer, according to GlobeNewswire PE. It is currently under evaluation in a Phase 2 trial for patients with head and neck cancer, building on the companies’ long-standing collaboration. As widely-known context, neoantigen vaccines represent a growing area in oncology, though specific outcomes depend on ongoing trials.
Leadership Perspectives
Dr. Alessandro Riva, Chairman and CEO of Transgene, stated that the agreement strengthens their position to pursue TG4050’s development using data from the ongoing Phase 2 trial and welcomes NEC as a shareholder, according to GlobeNewswire PE. This collaboration enables Transgene to advance the program toward potential commercialization and partnering.
